{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:22:44Z","timestamp":1795029764742,"version":"4.10.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including nausea, photophobia, or phonophobia) compared with placebo when administered during a migraine attack. The objective of this exploratory analysis was to examine the earliest time points that eptinezumab separated from placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) on headache- and migraine-associated symptoms when administered during a migraine attack.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>RELIEF, a multicenter, parallel-group, double-blind trial, occurred from November 7, 2019, through July 8, 2020. Adults considered candidates for preventive treatment were randomized to eptinezumab 100\u00a0mg (<jats:italic>N<\/jats:italic>\u2009=\u2009238) or placebo (<jats:italic>N<\/jats:italic>\u2009=\u2009242) administered intravenously over 30\u00a0min within 1\u20136\u00a0h of migraine onset. Outcome measures included headache pain freedom\/relief and absence of MBS, patient\u2019s choice of photophobia, phonophobia, or nausea, at regular intervals from 0.5 to 48\u00a0h after infusion start. Censoring was applied at time of acute rescue medication use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At hour 1, more eptinezumab-treated patients achieved headache pain freedom (9.7%), headache pain relief (38.7%), and absence of MBS (33.2%) versus placebo (4.1%, 26.9%, and 22.1%, respectively; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05 all), with separation from placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) through hour 48. Eptinezumab separated from placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) at hour 1 in absence-of-photophobia (29.4% vs 17.0%) and absence-of-phonophobia (41.2% vs 27.2%) and through hour 48. Initial separation from placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) in absence-of-nausea occurred at end-of-infusion (0.5\u00a0h; 36.7% vs 25.4%, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Preventive treatment with eptinezumab initiated during a migraine attack resulted in more patients achieving headache pain freedom\/relief and absence of MBS, with separation from placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) as early as 0.5\u20131\u00a0h following the start of infusion. Rapid resolution of headache- and migraine-associated symptoms by a peripherally acting, intravenously administered antibody suggest a peripheral site of pharmacological action for CGRP blockade.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04152083\">NCT04152083<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02714-1","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T07:04:09Z","timestamp":1654239849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Winner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chakhava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Krog Josiassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Lindsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"11","key":"2714_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2714_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/head.13708","volume":"60","author":"S Munjal","year":"2020","unstructured":"Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW, et al. Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) study. Headache. 2020;60(2):416\u201329. https:\/\/doi.org\/10.1111\/head.13708.","journal-title":"Headache"},{"issue":"1","key":"2714_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","volume":"374","author":"LF Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez LF, Raport CJ, Ojala EW, Dutzar B, Anderson K, Stewart E, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. JPET. 2020;374(1):93\u2013103. https:\/\/doi.org\/10.1124\/jpet.119.264671.","journal-title":"JPET"},{"key":"2714_CR4","unstructured":"VYEPTI [package insert]. In. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2021."},{"key":"2714_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","volume":"111","author":"N Ferri","year":"2016","unstructured":"Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2016.07.015.","journal-title":"Pharmacol Res"},{"issue":"10","key":"2714_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on Day 1 after dosing. Headache. 2020;60(10):2220\u201331. https:\/\/doi.org\/10.1111\/head.14007.","journal-title":"Headache"},{"issue":"23","key":"2714_CR7","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325(23):2348\u201356. https:\/\/doi.org\/10.1001\/jama.2021.7665.","journal-title":"JAMA"},{"issue":"3","key":"2714_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"2714_CR9","doi-asserted-by":"publisher","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2020;94(13):e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","DOI":"10.1212\/WNL.0000000000009169"},{"issue":"6","key":"2714_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpdd.345","volume":"6","author":"L Pellesi","year":"2017","unstructured":"Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6(6):534\u201347. https:\/\/doi.org\/10.1002\/cpdd.345.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"2714_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","journal-title":"Cephalalgia"},{"key":"2714_CR12","volume-title":"Migraine: Developing Drugs for Acute Treatment Guidance for Industry","author":"FDA","year":"2018","unstructured":"FDA. Migraine: Developing Drugs for Acute Treatment Guidance for Industry. 2018. (https:\/\/www.fda.gov\/media\/89829\/download Accessed 8\/4\/2021)."},{"issue":"6","key":"2714_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"H-C Diener","year":"2019","unstructured":"Diener H-C, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019;39(6):687\u2013710. https:\/\/doi.org\/10.1177\/0333102419828967.","journal-title":"Cephalalgia"},{"issue":"23","key":"2714_CR14","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813049.","journal-title":"N Engl J Med"},{"issue":"19","key":"2714_CR15","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398. https:\/\/doi.org\/10.1001\/jama.2019.16711.","journal-title":"JAMA"},{"issue":"5","key":"2714_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/0333102420970523","volume":"41","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, Adams AM, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia. 2021;41(5):546\u201360. https:\/\/doi.org\/10.1177\/0333102420970523.","journal-title":"Cephalalgia"},{"issue":"2","key":"2714_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1811090.","journal-title":"N Engl J Med"},{"issue":"1","key":"2714_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1129-2377-15-84","volume":"15","author":"FH Maniyar","year":"2014","unstructured":"Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. The origin of nausea in migraine-a PET study. J Headache Pain. 2014;15(1):84. https:\/\/doi.org\/10.1186\/1129-2377-15-84.","journal-title":"J Headache Pain."}],"updated-by":[{"DOI":"10.1186\/s12883-023-03368-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02714-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T08:04:02Z","timestamp":1693987442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02714-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02714-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12883-023-03368-3","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12883-023-03368-3","URL":"https:\/\/doi.org\/10.1186\/s12883-023-03368-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The independent ethics committee and\/or institutional review board for each site approved the study; there were a total of 57 sites: Alabama Clinical Therapeutics (Birmingham, AL, United States), Arizona Research Center (Phoenix, AZ, United States), Baptist Health Center for Clinical Research (Little Rock, AR, United States), Advanced Research Center (Anaheim, CA, United States), The Neurology Center of Southern California \u2013 Carlsbad (Carlsbad, CA, United States), Excell Research Inc. (Oceanside, CA, United States), Anderson Clinical Research (Redlands, CA, United States), University of Colorado Hospital (Aurora, CO, United States), Denver Neurological Clinic \u2013 Denver (Denver, CO, United States), Coastal Connecticut Research LLC (New London, CT, United States), Ki Health Partners LLC, dba New England Institute for Clinical Research (Stamford, CT, United States), The George Washington Medical Faculty Associates (Washington, District of Columbia, United States), Medicinae Doctor Clinical (Hallandale Beach, FL, United States), AGA Clinical trials (Hialeah, FL, United States), Meridien Research \u2013 Maitland (Maitland, FL, United States), Palm Beach Neurology and Premiere Research Institute, (West Palm Beach, FL, United States), Clinical Research of Central Florida (Winter Haven, FL, United States), Office of Doctor Frank Berenson (Atlanta, GA, United States), iResearch Atlanta, LLC (Decatur, GA, United States), Meridian Clinical Research\u2014Savannah Neurology Specialists (Savannah, GA, United States), Cedar Crosse Research Center (Chicago, IL, United States), College Park Family Care Center Physicians (Overland Park, KS, United States), Phoenix Medical Research (Prairie Village, KS, United States), Central Kentucky Research Associates (Lexington, KY, United States), Boston Clinical Trials (Boston, MA, United States), MedVadis Research Corporation, LLC (Waltham, MA, United States), Michigan Head Pain and Neurological Institute (Ann Arbor, MI, United States), Clinical Research Institute \u2013 Minneapolis (Minneapolis, MN, United States), Headache Neurology Research Institute (Ridgeland, MS, United States), StudyMetrix Research (Saint Peters, MO, United States), Clinvest Research (Springfield, MO, United States), Nevada Headache Institute (Las Vegas, NV, United States), Albuqerque Clinical Trials (Albuquerque, NM, United States), Dent Neurologic Institute \u2013 Amherst (Amherst, NY, United States), Integrative Clinical Trials (Brooklyn, NY, United States), CTI Clinical Research Center (Cincinnati, OH, United States), Aventiv Research \u2013 Columbus (Columbus, OH, United States), Hometown Urgent Care and Research\u2014Huber Heights (Dayton, OH, United States), Neuro-Behavioral Clinical Research Inc. (North Canton, OH, United States), Delricht Research (Tulsa, OK, United States), Summit Research Network (Portland, OR, United States), Frontier Clinical Research LLC (Smithfield, PA, United States), Coastal Carolina Research Center\u2013Mount Pleasant (Mount Pleasant, SC, United States), Chattanooga Medical Research LLC (Chattanooga, TN, United States), WR-ClinSearch LLC (Chattanooga, TN, United States), Holston Medical Group \u2013 Kingsport (Kingsport, TN, United States), Ventavia Research Group, LLC (Fort Worth, TX, United States), Texas Center for Drug Development Inc. (Houston, TX, United States), Ventavia Research Group, LLC (Keller, TX, United States), J. Lewis Research, Inc. \/Foothill Family Clinic (Salt Lake City, UT, United States), Northwest Clinical Research Center (Bellevue, WA, United States), Neuroscience Group (Neenah, WI, United States), Acad Fridon Todua Medical Center\u2013Ltd Research Institute of Clinical Medicine (Tbilisi, Georgia), Aversi Clinic (Tbilisi, Georgia), Multiprofile Clinica Consilium Medulla (Tbilisi, Georgia), Simon Khechinashvili University Clinic (Tbilisi, Georgia), and Israel-Georgia Medical Research Clinic Helsicore (Tbilisi, Georgia). The RELIEF study was conducted in accordance with standards of Good Clinical Practice as defined by the International Conference on Harmonisation and all applicable federal and local regulations. All study documentation was approved by the local review board at each site or by a central institutional review board or ethics committee. All patients provided written informed consent prior to their participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JA has received research support from AbbVie, Biohaven, Lilly, Satsuma, and Zosano; consulting fees from AbbVie, Aeon, Amgen, Axsome, Biodelivery Sciences International, Biohaven, GlaxoSmithKline, Impel, Lilly, Lundbeck, Nesos, Satsuma, Teva, and Theranica; and speaker fees from AbbVie, Amgen, Biohaven, Lilly, Lundbeck, and Teva.PM has received personal fees and research support from AbbVie, Amgen\/Novartis, Biohaven, Lilly, Lundbeck, and Teva.PKW has received consulting fees from AbbVie, Amgen, Biohaven, Lilly, Lundbeck, Novartis, and Teva; served on Speaker bureaus for AbbVie, Amgen, Biohaven, Lilly, Lundbeck, Novartis, and Teva; and received research support from AbbVie, Amgen, AZ, Biogen, Lilly, Lundbeck, Novartis, Supernus, and Teva.GC has nothing to declare.MKJ, AL, BS, and AE are full-time employees of H. Lundbeck A\/S.RC was an employee of Lundbeck or one of its subsidiary companies at the time of study and manuscript development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}